SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors
European Journal of Nuclear Medicine and Molecular Imaging · 2025-12 · 53 (1) · 116-127
DOI: 10.1007/s00259-025-07336-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 02.06.2025. Verfasst von Natalie Hasenauer und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacherstraße 6, 97080, Würzburg, Germany. Hasenauer_N@ukw.de. Hauptthemen laut MEDLINE: Meningioma, Receptors, Somatostatin, Octreotide, Meningeal Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitätsklinikum Würzburg.
Abstract (Originalsprache)
Purpose
This study evaluates safety and efficacy of peptide receptor radionuclide therapy (PRRT) as a stand-alone treatment for recurrent meningiomas and investigates the prognostic value of laboratory markers and quantitative PET parameters.
Methods
The single-center study includes 32 patients with recurrent meningioma, who underwent PRRT with [ 177 Lu]Lu-DOTATOC/-TATE. Pre-treatment assessments comprised [ 68 Ga]Ga-DOTATOC PET imaging, routine hematology and serum chemistry analysis. Outcomes including progression-free survival (PFS), overall survival (OS), and treatment related toxicity, were retrospectively evaluated using Kaplan–Meier survival analysis and Cox regression models.
Results
PRRT showed only mild hematological and renal toxicity, with most adverse events being low-grade (87%). OS was significantly shorter in patients with WHO grade III meningiomas (10 months) compared to grade I (not reached, HR 4.77, p < 0.01) and grade II (47 months, HR 4.05, p = 0.01). Similarly, PFS was shorter in patients with WHO grade III meningiomas (4.5 months) compared to grade I (17 months, HR 6.47, p < 0.001) and grade II (17 months, HR 2.71, p = 0.02). In multivariable analysis, only higher WHO grade was an independent predictor of disease progression, while baseline PET and laboratory parameters showed no consistent association. Furthermore, increase of SSTR-positive tumor volume in follow-up PET was associated with shorter PFS (HR 1.02, p = 0.02).
Conclusion
PRRT is a safe treatment option and appears to have a favourable effect in patients with recurrent meningiomas. WHO tumor grade is the strongest predictor of PFS and OS, while baseline PET parameters appear to have no prognostic value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacherstraße 6, 97080, Würzburg, Germany. Hasenauer_N@ukw.de.
- Department of Nuclear Medicine, University Hospital Würzburg, Oberdürrbacherstraße 6, 97080, Würzburg, Germany.
- Department of Radiation Oncology, University Hospital Wuerzburg, Würzburg, Germany.
- Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany.
ORCID-Profile: Natalie Hasenauer
Förderung
- Universitätsklinikum Würzburg
Zitieren
APA
Hasenauer, N., Müller, M., Hänscheid, H., Serfling, S. E., Michalski, K., Heinrich, M., Polat, B., Buck, A. K., Werner, R. A., & Hartrampf, P. E. (2025). SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors. European Journal of Nuclear Medicine and Molecular Imaging, 53(1), 116-127. https://doi.org/10.1007/s00259-025-07336-6
Vancouver
Hasenauer N, Müller M, Hänscheid H, Serfling SE, Michalski K, Heinrich M, et al. SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors. European Journal of Nuclear Medicine and Molecular Imaging. 2025;53(1):116-127. doi:10.1007/s00259-025-07336-6
BibTeX
@article{Hasenauer2025,
author = {Hasenauer, Natalie and Müller, Miriam and Hänscheid, Heribert and Serfling, Sebastian E and Michalski, Kerstin and Heinrich, Marieke and Polat, Bülent and Buck, Andreas K and Werner, Rudolf A and Hartrampf, Philipp E},
title = {SSTR-directed peptide receptor radionuclide therapy for recurrent meningiomas: analysis of safety, efficacy and prognostic factors},
journal = {European Journal of Nuclear Medicine and Molecular Imaging},
year = {2025},
volume = {53},
number = {1},
pages = {116--127},
doi = {10.1007/s00259-025-07336-6}
}
EUVIMED